دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes
Angus G. Jones, Timothy J. McDonald, Beverley M. Shields, William Hagopian and Andrew T. Hattersley
doi : 10.2337/dc20-2834
Diabetes Care 2021 Jun; 44 (6): 1243-1251.
Latent autoimmune diabetes of adults (LADA) is typically defined as a new diabetes diagnosis after 35 years of age, presenting with clinical features of type 2 diabetes, in whom a type 1 diabetes–associated islet autoantibody is detected. Identifying autoimmune diabetes is important since the prognosis and optimal therapy differ. However, the existing LADA definition identifies a group with clinical and genetic features intermediate between typical type 1 and type 2 diabetes. It is unclear whether this is due to 1) true autoimmune diabetes with a milder phenotype at older onset ages that initially appears similar to type 2 diabetes but later requires insulin, 2) a disease syndrome where the pathophysiologies of type 1 and type 2 diabetes are both present in each patient, or 3) a heterogeneous group resulting from difficulties in classification. Herein, we suggest that difficulties in classification are a major component resulting from defining LADA using a diagnostic test—islet autoantibody measurement—with imperfect specificity applied in low-prevalence populations. This yields a heterogeneous group of true positives (autoimmune type 1 diabetes) and false positives (nonautoimmune type 2 diabetes). For clinicians, this means that islet autoantibody testing should not be undertaken in patients who do not have clinical features suggestive of autoimmune diabetes: in an adult without clinical features of type 1 diabetes, it is likely that a single positive antibody will represent a false-positive result. This is in contrast to patients with features suggestive of type 1 diabetes, where false-positive results will be rare. For researchers, this means that current definitions of LADA are not appropriate for the study of autoimmune diabetes in later life. Approaches that increase test specificity, or prior likelihood of autoimmune diabetes, are needed to avoid inclusion of participants who have nonautoimmune (type 2) diabetes. Improved classification will allow improved assignment of prognosis and therapy as well as an improved cohort in which to analyze and better understand the detailed pathophysiological components acting at onset and during disease progression in late-onset autoimmune diabetes.
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
Guillaume Marquis-Gravel and Jean-Claude Tardif
doi : 10.2337/dci20-0076
Diabetes Care 2021 Jun; 44 (6): 1252-1253.
Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes
Ashleigh R. Homer, Frances C. Taylor, Paddy C. Dempsey, Michael J. Wheeler, Parneet Sethi, Melanie K. Townsend, Megan S. Grace, Daniel J. Green, Neale D. Cohen, Robyn N. Larsen, Bronwyn A. Kingwell, Neville Owen and David W. Dunstan
doi : 10.2337/dc20-1410
Diabetes Care 2021 Jun; 44 (6): 1254-1263.
OBJECTIVE To determine whether interrupting sitting with brief bouts of simple resistance activities (SRAs) at different frequencies improves postprandial glucose, insulin, and triglycerides in adults with medication-controlled type 2 diabetes (T2D).
Spouse’s Diabetes Status and Incidence of Depression and Anxiety: An 18-Year Prospective Study
Jannie Nielsen, Solveig A. Cunningham, Mohammed K. Ali and Shivani A. Patel
doi : 10.2337/dc20-2652
Diabetes Care 2021 Jun; 44 (6): 1264-1272
OBJECTIVE We investigated the risk of depression and anxiety in people whose spouse did or did not have diabetes. We also examined associations between depression and anxiety and severity of spouse’s diabetes.
Cognitive Function in Adolescents and Young Adults With Youth-Onset Type 1 Versus Type 2 Diabetes: The SEARCH for Diabetes in Youth Study
Allison L.B. Shapiro, Dana Dabelea, Jeanette M. Stafford, Ralph D’Agostino, Catherine Pihoker, Angela D. Liese, Amy S. Shah, Anna Bellatorre, Jean M. Lawrence, Leora Henkin, Sharon Saydah and Greta Wilkening, for the SEARCH for Diabetes in Youth Study Group
doi : 10.2337/dc20-2308
Diabetes Care 2021 Jun; 44 (6): 1273-1280
OBJECTIVE Poor cognition has been observed in children and adolescents with youth-onset type 1 (T1D) and type 2 diabetes (T2D) compared with control subjects without diabetes. Differences in cognition between youth-onset T1D and T2D, however, are not known. Thus, using data from SEARCH for Diabetes in Youth, a multicenter, observational cohort study, we tested the association between diabetes type and cognitive function in adolescents and young adults with T1D (n = 1,095) or T2D (n = 285).
Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis
Danielle K. Longmore, Jessica E. Miller, Siroon Bekkering, Christoph Saner, Edin Mifsud, Yanshan Zhu, Richard Saffery, Alistair Nichol, Graham Colditz, Kirsty R. Short and David P. Burgner, on behalf of the International BMI-COVID consortium
doi : 10.2337/dc20-2676
Diabetes Care 2021 Jun; 44 (6): 1281-1290
OBJECTIVE Obesity is an established risk factor for severe coronavirus disease 2019 (COVID-19), but the contribution of overweight and/or diabetes remains unclear. In a multicenter, international study, we investigated if overweight, obesity, and diabetes were independently associated with COVID-19 severity and whether the BMI-associated risk was increased among those with diabetes.
Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants
Heiner Claessen, Maria Narres, Tatjana Kvitkina, Adrian Wilk, Heiko Friedel, Christian Günster, Falk Hoffmann, Michael Koch, Karin Jandeleit-Dahm and Andrea Icks
doi : 10.2337/dc20-2477
Diabetes Care 2021 Jun; 44 (6): 1291-1299
OBJECTIVE Epidemiological studies have shown contradictory results regarding the time trend of end-stage renal disease (ESRD) in people with diabetes. This study aims to analyze the incidence of ESRD, defined as chronic renal replacement therapy (RRT), to investigate time trends among people with and without diabetes in Germany and to examine whether these patterns differ by age and sex.
Trends in Receipt of American Diabetes Association Guideline-Recommended Care Among U.S. Adults With Diabetes: NHANES 2005–2018
Jung-Im Shin, Dan Wang, Gail Fernandes, Natalie Daya, Morgan E. Grams, Sherita H. Golden, Swapnil Rajpathak and Elizabeth Selvin
doi : 10.2337/dc20-2541
Diabetes Care 2021 Jun; 44 (6): 1300-1308
OBJECTIVE To characterize national trends and characteristics of adults with diabetes receiving American Diabetes Association (ADA) guideline-recommended care.
Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study
Ionut Bebu, Sareh Keshavarzi, Xiaoyu Gao, Barbara H. Braffett, Angelo J. Canty, William H. Herman, Trevor J. Orchard, Samuel Dagogo-Jack, David M. Nathan, John M. Lachin and Andrew D. Paterson, on behalf of the DCCT/EDIC Research Group
doi : 10.2337/dc20-2388
Diabetes Care 2021 Jun; 44 (6): 1309-1316
OBJECTIVE The role of genetic factors in the risk of cardiovascular disease (CVD) for patients with type 1 diabetes (T1D) remains unknown. We therefore examined whether previously identified genetic factors for coronary artery disease (CAD) are associated with the risk of CVD above and beyond established demographic and clinical factors in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study.
Incremental Dental Expenditures Associated With Diabetes Among Noninstitutionalized U.S. Adults Aged ?18 Years Old in 2016–2017
Yu Chen, Ping Zhang, Elizabeth T. Luman, Susan O. Griffin and Deborah B. Rolka
doi : 10.2337/dc20-2744
Diabetes Care 2021 Jun; 44 (6): 1317-1323
OBJECTIVE Diabetes is associated with poor oral health, but incremental expenditures for dental care associated with diabetes in the U.S. are unknown. We aimed to quantify these incremental expenditures per person and for the nation.
Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial
Ling Qu, Xiaochun Liang, Guoqing Tian, Gaili Zhang, Qunli Wu, Xiumei Huang, Yazhong Cui, Yuling Liu, Zhufang Shen, Changqing Xiao, Yingfen Qin, Heng Miao, Yongyan Zhang, Ziling Li, Shandong Ye, Xuezhi Zhang, Jing Yang, Guiwen Cao, Yi Li, Gangyi Yang, Ji Hu, Xiaoyue Wang, Zhengfang Li, Yukun Li, Xiuzhen Zhang, Guangde Zhang, Li Chen, Wenjin Hua, Ming Yu, Chunyan Lu, Xiaomei Zhang and Hong Jiang
doi : 10.2337/dc20-2109
Diabetes Care 2021 Jun; 44 (6): 1324-1333
OBJECTIVE This study aimed to evaluate the efficacy and safety of mulberry twig alkaloids (Sangzhi alkaloids [SZ-A]) in the treatment of type 2 diabetes (T2D).
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial
Yvo J.M. Op den Kamp, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Russell Esterline, Matthijs K.C. Hesselink, Joris Hoeks, Vera B. Schrauwen-Hinderling, Bas Havekes, Jan Oscarsson, Esther Phielix and Patrick Schrauwen
doi : 10.2337/dc20-2887
Diabetes Care 2021 Jun; 44 (6): 1334-1343
OBJECTIVE SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes.
Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
Yasser Albogami, Kenneth Cusi, Michael J. Daniels, Yu-Jung J. Wei and Almut G. Winterstein
doi : 10.2337/dc20-1794
Diabetes Care 2021 Jun; 44 (6): 1344-1352
OBJECTIVE Emerging data from animal and human pilot studies suggest potential benefits of glucagon-like peptide 1 receptor agonists (GLP-1RA) on lung function. We aimed to assess the association of GLP-1RA and chronic lower respiratory disease (CLRD) exacerbation in a population with comorbid type 2 diabetes (T2D) and CLRD.
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
Dario Giugliano, Miriam Longo, Paola Caruso, Rosa Di Fraia, Lorenzo Scappaticcio, Maurizio Gicchino, Michela Petrizzo, Giuseppe Bellastella, Maria Ida Maiorino and Katherine Esposito
doi : 10.2337/dc20-2623
Diabetes Care 2021 Jun; 44 (6): 1353-1360.
OBJECTIVE BEYOND trial evaluated the feasibility of either basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1RA) or basal insulin plus sodium–glucose cotransporter 2 inhibitor (SGLT2i) to replace a full basal-bolus insulin (BBI) regimen in participants with type 2 diabetes and inadequate glycemic control.
Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
Thomas R. Pieber, Ronnie Aronson, Ulrike H?velmann, Julie Willard, Leona Plum-M?rschel, Kim M. Knudsen, Benedikte Bandak and Ramin Tehranchi
doi : 10.2337/dc20-2995
Diabetes Care 2021 Jun; 44 (6): 1361-1367
OBJECTIVE To evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes.
Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study
Ronan Roussel, Jean-Pierre Riveline, Eric Vicaut, Gérard de Pouvourville, Bruno Detournay, Corinne Emery, Fleur Levrat-Guillen and Bruno Guerci
doi : 10.2337/dc20-1690
Diabetes Care 2021 Jun; 44 (6): 1368-1376
OBJECTIVE The RELIEF study assessed rates of hospitalization for acute diabetes complications in France before and after initiation of the FreeStyle Libre system.
ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes
Yawa Abouleka, Kamel Mohammedi, Charlyne Carpentier, Severine Dubois, Pierre Gourdy, Jean-François Gautier, Ronan Roussel, André Scheen, François Alhenc-Gelas, Samy Hadjadj, Gilberto Velho and Michel Marre
doi : 10.2337/dc20-3036
Diabetes Care 2021 Jun; 44 (6): 1377-1384
OBJECTIVE The deletion (D) allele of the ACE insertion/deletion (I/D) polymorphism is a risk factor for diabetic kidney disease. We assessed its contribution to long-term kidney outcomes and all-cause death in patients with long-standing type 1 diabetes.
The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
Juraj Koska, Raymond Q. Migrino, Keith C. Chan, Kelly Cooper-Cox and Peter D. Reaven
doi : 10.2337/dc20-2014
Diabetes Care 2021 Jun; 44 (6): 1385-1392
OBJECTIVE Glucagon-like peptide 1 receptor agonists (GLP-1RAs) improved multiple proatherogenic risk factors and reduced cardiovascular events in recent clinical trials, suggesting that they may slow progression of atherosclerosis. We tested whether exenatide once weekly reduces carotid plaque progression in individuals with type 2 diabetes.
Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study
You-jung Choi, Kyung-Do Han, Eue-Keun Choi, Jin-Hyeung Jung, So-Ryoung Lee, Seil Oh and Gregory Y.H. Lip
doi : 10.2337/dc20-2607
Diabetes Care 2021 Jun; 44 (6): 1393-1401
OBJECTIVE To investigate the effects of alcohol abstinence on prevention of new-onset atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM).
Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes
Kari Anne Sveen, Kristine Bech Holte, Mona Svanteson, Kristian F. Hanssen, Jan Nilsson, Eva Bengtsson and Tore Julsrud Berg
doi : 10.2337/dc20-2089
Diabetes Care 2021 Jun; 44 (6): 1402-1409
OBJECTIVE Methylglyoxal (MGO), a reactive aldehyde forming advanced glycation end products (AGEs), is increased in diabetes and recognized by the immune system, resulting in anti-AGE–specific autoantibodies. The association of these immune responses with macro- and microvascular complications in type 1 diabetes remains unclarified. We investigated associations between MGO-modified apolipoprotein B100 (apoB100) and apoB100 peptide 5 (MGO-p5) autoantibodies and coronary atherosclerosis and retinopathy in type 1 diabetes.
A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
Arshiya Mariam, Galen Miller-Atkins, Kevin M. Pantalone, Robert S. Zimmerman, John Barnard, Michael W. Kattan, Hetal Shah, Howard L. McLeod, Alessandro Doria, Michael J. Wagner, John B. Buse, Alison A. Motsinger-Reif and Daniel M. Rotroff
doi : 10.2337/dc20-2700
Diabetes Care 2021 Jun; 44 (6): 1410-1418
OBJECTIVE Current type 2 diabetes (T2D) management contraindicates intensive glycemia treatment in patients with high cardiovascular disease (CVD) risk and is partially motivated by evidence of harms in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Heterogeneity in response to intensive glycemia treatment has been observed, suggesting potential benefit for some individuals.
Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT)
Jelle M. Beernink, Milou M. Oosterwijk, Kamlesh Khunti, Pankaj Gupta, Prashanth Patel, Job F.M. van Boven, Hiddo J. Lambers Heerspink, Stephan J.L. Bakker, Gerjan Navis, Roos M. Nijboer and Gozewijn D. Laverman
doi : 10.2337/dc20-2533
Diabetes Care 2021 Jun; 44 (6): 1419-1425
OBJECTIVE To assess adherence to the three main drug classes in real-world patients with type 2 diabetes using biochemical urine testing, and to determine the association of nonadherence with baseline demographics, treatment targets, and complications.
Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study
Maoxiang Zhao, Lulu Song, Lan Sun, Miao Wang, Chi Wang, Siyu Yao, Yao Li, Cuijuan Yun, Sijin Zhang, Yizhen Sun, Ziwei Hou, Shouling Wu and Hao Xue
doi : 10.2337/dc20-2375
Diabetes Care 2021 Jun; 44 (6): 1426-1432
OBJECTIVE We aimed to explore the associations between type 2 diabetes onset age and cardiovascular disease (CVD) and all-cause mortality in the Chinese population.
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra, Tao Wang, Kishore M. Gadde, Jan Oscarsson, Michael Stumvoll, Lutz Jermutus, Boaz Hirshberg and Philip Ambery
doi : 10.2337/dc20-2151
Diabetes Care 2021 Jun; 44 (6): 1433-1442
OBJECTIVE Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes.
Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care
Caitlin Colling, Steven J. Atlas and Deborah J. Wexler
doi : 10.2337/dc21-0013
Diabetes Care 2021 Jun; 44 (6): 1443-1446
OBJECTIVE We aimed to identify the proportion of primary care patients meeting criteria for sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for cardiorenal comorbidities per 2021 American Diabetes Association (ADA) Standards of Care recommendations using readily available electronic health record (EHR) characteristics.
The Rapid Transition to Telemedicine and Its Effect on Access to Care for Patients With Type 1 Diabetes During the COVID-19 Pandemic
Daniel R. Tilden, Karishma A. Datye, Daniel J. Moore, Benjamin French and Sarah S. Jaser
doi : 10.2337/dc20-2712
Diabetes Care 2021 Jun; 44 (6): 1447-1450
OBJECTIVE We compared the uptake of telemedicine for diabetes care across multiple demographic groups during the coronavirus disease 2019 pandemic to understand the impact of telemedicine adoption on access to care.
Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic
Lily C. Chao, Alaina P. Vidmar and Senta Georgia
doi : 10.2337/dc20-2733
Diabetes Care 2021 Jun; 44 (6): 1451-1453
OBJECTIVE The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) on the incidence of new-onset type 2 diabetes and diabetic ketoacidosis (DKA) is unclear. It is unknown whether the coincidence of DKA noted in adult patients with type 2 diabetes is an issue for youth during the coronavirus disease 2019 pandemic.
Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
Ele Ferrannini and Julio Rosenstock
doi : 10.2337/dc21-er06
Diabetes Care 2021 Jun; 44 (6): 1454
Erratum. Relations Between Subclinical Disease Markers and Type 2 Diabetes, Metabolic Syndrome, and Incident Cardiovascular Disease: The Jackson Heart Study. Diabetes Care 2015;38:1082–1088
Vanessa Xanthakis, Jung Hye Sung, Tandaw E. Samdarshi, Alethea N. Hill, Solomon K. Musani, Mario Sims, Kamel A. Gharaibeh, Philip R. Liebson, Herman A. Taylor, Ramachandran S. Vasan and Ervin R. Fox
doi : 10.2337/dc21-er06a
Diabetes Care 2021 Jun; 44 (6): 1455
Erratum. Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? Diabetes Care 2021;44:280–289
Helen L. Tanner, Marloes Dekker Nitert, Leonie K. Callaway and Helen L. Barrett
doi : 10.2337/dc21-er06b
Diabetes Care 2021 Jun; 44 (6): 1456
Erratum. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care 2021;44:1062–1069
Vasudha Ahuja, Pasi Aronen, T.A. Pramodkumar, Helen Looker, Angela Chetrit, Aini H. Bloigu, Auni Juutilainen, Cristina Bianchi, Lucia La Sala, Ranjit Mohan Anjana, Rajendra Pradeepa, Ulagamadesan Venkatesan, Sarvanan Jebarani, Viswanathan Baskar, Teresa Vanessa Fiorentino, Patrick Timpel, Ralph A. DeFronzo, Antonio Ceriello, Stefano Del Prato, Muhammad Abdul-Ghani, Sirkka Kein?nen-Kiukaanniemi, Rachel Dankner, Peter H. Bennett, William C. Knowler, Peter Schwarz, Giorgio Sesti, Rie Oka, Viswanathan Mohan, Leif Groop, Jaakko Tuomilehto, Samuli Ripatti, Michael Bergman and Tiinamaija Tuomi
doi : 10.2337/dc21-er06c
Diabetes Care 2021 Jun; 44 (6): 1457
Is Shelter-in-Place Policy Related to Mail Order Pharmacy Use and Racial/Ethnic Disparities for Patients With Diabetes?
Tainayah W. Thomas, Wendy T. Dyer, Maher Yassin, Romain Neugebauer, Andrew J. Karter and Julie A. Schmittdiel
doi : 10.2337/dc20-2686
Diabetes Care 2021 Jun; 44 (6): e113-e114
Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes
Tadashi Imafuku, Hiroshi Watanabe, Kentaro Oniki, Akira Yoshida, Hiromasa Kato, Takehiro Nakano, Kai Tokumaru, Issei Fujita, Nanaka Arimura, Hitoshi Maeda, Yuki Sakamoto, Nozomi Kondo, Ayami Morita, Junji Saruwatari, Motoko Tanaka, Kazutaka Matsushita, Takashi Wada, Masafumi Fukagawa, Masaki Otagiri, Michael L. Fitzgerald, Hideaki Jinnouchi and Toru Maruyama
doi : 10.2337/dc20-3003
Diabetes Care 2021 Jun; 44 (6): e115-e117
Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting
Luz E. Castellanos, Courtney A. Balliro, Jordan S. Sherwood, Rabab Jafri, Mallory A. Hillard, Evelyn Greaux, Rajendranath Selagamsetty, Hui Zheng, Firas H. El-Khatib, Edward R. Damiano and Steven J. Russell
doi : 10.2337/dc20-1086
Diabetes Care 2021 Jun; 44 (6): e118-e120
Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards
Halis K. Akturk, Shivani Agarwal, Lilian Hoffecker and Viral N. Shah
doi : 10.2337/dc20-3063
Diabetes Care 2021 Jun; 44 (6): e121-e123
Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes
Peter S. Hamblin, Rosemary Wong, Elif I. Ekinci, Shoshana Sztal-Mazer, Shananthan Balachandran, Aviva Frydman, Timothy P. Hanrahan, Raymond Hu, Shara N. Ket, Alan Moss, Mark Ng, Sashikala Ragunathan and Leon A. Bach
doi : 10.2337/dc21-0256
Diabetes Care 2021 Jun; 44 (6): e124-e126
Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study
Daniele Scoccimarro, Giacomo Cipani, Ilaria Dicembrini and Edoardo Mannucci
doi : 10.2337/dc21-0308
Diabetes Care 2021 Jun; 44 (6): e127-e128
The Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women
Lynn Guo, Nancy P. Gordon, Malini Chandra, Olumayowa Dayo and Joan C. Lo
doi : 10.2337/dc21-0373
Diabetes Care 2021 Jun; 44 (6): e129-e130
The Prevalence of Food Insecurity Is Highest Among Americans for Whom Diet Is Most Critical to Health
James B. Kirby, Didem Bernard and Lan Liang
doi : 10.2337/dc20-3116
Diabetes Care 2021 Jun; 44 (6): e131-e132
Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic
Jonathan Valabhji, Emma Barron, Eszter P. Vamos, Ketan Dhatariya, Frances Game, Partha Kar, Andy Weaver, Sophia Verma, Bob Young and Kamlesh Khunti
doi : 10.2337/dc20-2852
Diabetes Care 2021 Jun; 44 (6): e133-e135
Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Shay Brikman and Guy Dori
doi : 10.2337/dc21-0310
Diabetes Care 2021 Jun; 44 (6): e136
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Ian J. Neeland, Takatoshi Kasai, Silvio E. Inzucchi, Brian S. Wojeck, Henry K. Yaggi and Odd Erik Johansen, on behalf of the EMPA-REG OUTCOME Investigators
doi : 10.2337/dci21-0009
Diabetes Care 2021 Jun; 44 (6): e137-e138.
Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
Helena Bleken ?stergaard, Joep van der Leeuw, Frank L.J. Visseren and Jan Westerink
doi : 10.2337/dc21-0364
Diabetes Care 2021 Jun; 44 (6): e139
Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
Dorte Vistisen, Gregers S. Andersen, Adam Hulman, Stuart J. McGurnaghan, Helen M. Colhoun, Jan E. Henriksen, Reimar W. Thomsen, Frederik Persson, Peter Rossing and Marit E. J?rgensen
doi : 10.2337/dci21-0010
Diabetes Care 2021 Jun; 44 (6): e140-e141
